Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity

210Citations
Citations of this article
248Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Current influenza vaccines only confer protection against homologous viruses. We synthesized pulmonary surfactant (PS)-biomimetic liposomes encapsulating 2',3'-cyclic guanosine monophosphate- adenosine monophosphate (cGAMP), an agonist of the interferon gene inducer STING (stimulator of interferon genes). The adjuvant (PS-GAMP) vigorously augmented influenza vaccine-induced humoral and CD8+ T cell immune responses in mice by simulating the early phase of viral infection without concomitant excess inflammation. Two days after intranasal immunization with PS-GAMP-adjuvanted H1N1 vaccine, strong cross-protection was elicited against distant H1N1 and heterosubtypic H3N2, H5N1, and H7N9 viruses for at least 6 months while maintaining lung-resident memory CD8+ T cells. Adjuvanticity was then validated in ferrets. When alveolar epithelial cells (AECs) lacked Sting or gap junctions were blocked, PS-GAMP-mediated adjuvanticity was substantially abrogated in vivo. Thus, AECs play a pivotal role in configuring heterosubtypic immunity.

Cite

CITATION STYLE

APA

Wang, J., Li, P., Yu, Y., Fu, Y., Jiang, H., Lu, M., … Wu, M. X. (2020). Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science, 367(6480). https://doi.org/10.1126/science.aau0810

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free